Linked Life Data

20715711

Source:http://linkedlifedata.com/resource/pubmed/id/20715711

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-8-18
pubmed:abstractText
Last few years vancomycin-intermediate S. aureus and vancomycin-resistent S. aureus have emerged, giving us a task to reevaluate susceptiblity to vancomycin in treatment of methicillin-resistent S. aureus (MRSA) infections. It is also oportunity to review necessity for new generation of antibiotics in treatment of MRSA infections. Efficacy of vancomycin treatment in MRSA bacteriemia is associated with minimal inhibitory concentration (MIC) and speed of killing colonies. There is an increased probability of failure in treatment of MRSA bacteremia when there are high vancomycin MIC in vitro. That's one of the reasons why there is novel antibiotic therapy for MRSA investigated, especially daptomycin and linezolid. Daptomycin is lipopeptide and an important optional antibiotic in MRSA infections treatment: bacteremia and endocarditis, even the tricuspidal valve endocarditis. Linezolid, as novel oxazolidinon, has shown good activity against gram-positive bacteria, especially in treatment of nosocomial pneumonia and complicated skin and soft tissue infections caused by MRSA.
pubmed:language
hrv
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0024-3477
pubmed:author
pubmed:issnType
Print
pubmed:volume
132 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11-3
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].
pubmed:affiliation
Zavod za intenzivnu medicinu i neuroinfektologiju, Klinika za infektivne bolesti "Dr. Fran Mihaljevi?", Zagreb.
pubmed:publicationType
Journal Article, English Abstract, Review